CN107119021A - Pd‑1敲除cd19car‑t细胞的制备 - Google Patents
Pd‑1敲除cd19car‑t细胞的制备 Download PDFInfo
- Publication number
- CN107119021A CN107119021A CN201710539385.2A CN201710539385A CN107119021A CN 107119021 A CN107119021 A CN 107119021A CN 201710539385 A CN201710539385 A CN 201710539385A CN 107119021 A CN107119021 A CN 107119021A
- Authority
- CN
- China
- Prior art keywords
- cells
- plasmids
- car
- cell
- cd19car
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101710089372 Programmed cell death protein 1 Proteins 0.000 title claims abstract description 28
- 102100040678 Programmed cell death protein 1 Human genes 0.000 title claims abstract description 23
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 239000013612 plasmid Substances 0.000 claims abstract description 35
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims abstract description 21
- 230000005611 electricity Effects 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 13
- 108091027544 Subgenomic mRNA Proteins 0.000 claims abstract description 11
- 238000001890 transfection Methods 0.000 claims abstract description 10
- 108091033409 CRISPR Proteins 0.000 claims abstract description 8
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims abstract description 8
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims abstract description 8
- 102000008579 Transposases Human genes 0.000 claims abstract description 8
- 108010020764 Transposases Proteins 0.000 claims abstract description 8
- 230000003321 amplification Effects 0.000 claims abstract description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 7
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 7
- 239000011324 bead Substances 0.000 claims abstract description 6
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 6
- 230000008878 coupling Effects 0.000 claims abstract description 4
- 238000010168 coupling process Methods 0.000 claims abstract description 4
- 238000005859 coupling reaction Methods 0.000 claims abstract description 4
- 210000004027 cell Anatomy 0.000 claims description 71
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 20
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 17
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 17
- 238000005119 centrifugation Methods 0.000 claims description 11
- 108020003175 receptors Proteins 0.000 claims description 9
- 102000005962 receptors Human genes 0.000 claims description 9
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 claims description 8
- 210000005259 peripheral blood Anatomy 0.000 claims description 7
- 239000011886 peripheral blood Substances 0.000 claims description 7
- 239000003146 anticoagulant agent Substances 0.000 claims description 6
- 229940127219 anticoagulant drug Drugs 0.000 claims description 6
- 238000000926 separation method Methods 0.000 claims description 6
- 230000031146 intracellular signal transduction Effects 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 230000000139 costimulatory effect Effects 0.000 claims description 4
- 210000004698 lymphocyte Anatomy 0.000 claims description 4
- 239000002609 medium Substances 0.000 claims description 4
- 229950010131 puromycin Drugs 0.000 claims description 4
- 239000002356 single layer Substances 0.000 claims description 4
- 102100028113 Granulocyte-macrophage colony-stimulating factor receptor subunit alpha Human genes 0.000 claims description 3
- 101000916625 Homo sapiens Granulocyte-macrophage colony-stimulating factor receptor subunit alpha Proteins 0.000 claims description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 101710135898 Myc proto-oncogene protein Proteins 0.000 claims description 2
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims description 2
- 101710150448 Transcriptional regulator Myc Proteins 0.000 claims description 2
- 239000006143 cell culture medium Substances 0.000 claims description 2
- 238000012549 training Methods 0.000 claims description 2
- 230000006044 T cell activation Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 210000004976 peripheral blood cell Anatomy 0.000 claims 1
- 239000013603 viral vector Substances 0.000 abstract 1
- 241000700605 Viruses Species 0.000 description 9
- 238000011282 treatment Methods 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 208000032839 leukemia Diseases 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000004324 lymphatic system Anatomy 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 238000012815 AlphaLISA Methods 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 206010059484 Haemodilution Diseases 0.000 description 1
- 102100022132 High affinity immunoglobulin epsilon receptor subunit gamma Human genes 0.000 description 1
- 108091010847 High affinity immunoglobulin epsilon receptor subunit gamma Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- IGLKELDWPZFFKF-UHFFFAOYSA-N OC(C1=CC=CC=C1C(O)=O)=O.OC(C1=CC=CC=C1C(O)=O)=O.OC(C1=CC=CC=C1C(O)=O)=O.P.P Chemical compound OC(C1=CC=CC=C1C(O)=O)=O.OC(C1=CC=CC=C1C(O)=O)=O.OC(C1=CC=CC=C1C(O)=O)=O.P.P IGLKELDWPZFFKF-UHFFFAOYSA-N 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710539385.2A CN107119021A (zh) | 2017-07-04 | 2017-07-04 | Pd‑1敲除cd19car‑t细胞的制备 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710539385.2A CN107119021A (zh) | 2017-07-04 | 2017-07-04 | Pd‑1敲除cd19car‑t细胞的制备 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107119021A true CN107119021A (zh) | 2017-09-01 |
Family
ID=59731156
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710539385.2A Pending CN107119021A (zh) | 2017-07-04 | 2017-07-04 | Pd‑1敲除cd19car‑t细胞的制备 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107119021A (zh) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107699547A (zh) * | 2017-09-05 | 2018-02-16 | 上海科技大学 | Pd‑1基因沉默的靶向cd133的car t细胞及其应用 |
CN108440674A (zh) * | 2018-04-28 | 2018-08-24 | 杭州荣泽生物科技有限公司 | 一种Trop-2特异性嵌合抗原受体细胞制备及其用途 |
CN108531457A (zh) * | 2018-04-10 | 2018-09-14 | 杭州荣泽生物科技有限公司 | 一种Cas9/RNP敲除T细胞PD-1和LAG3基因及制备CAR-T细胞的方法 |
CN108913718A (zh) * | 2018-07-20 | 2018-11-30 | 苏州茂行生物科技有限公司 | 一种靶向EGFR vⅢ的CAR-T细胞的制备方法及应用 |
CN109652380A (zh) * | 2019-01-25 | 2019-04-19 | 苏州茂行生物科技有限公司 | 基于碱基编辑靶向LewisY的CAR-T细胞及其制备方法和应用 |
CN109837244A (zh) * | 2017-11-25 | 2019-06-04 | 深圳宾德生物技术有限公司 | 一种敲除pd1的靶向cd19的嵌合抗原受体t细胞及其制备方法和应用 |
CN109971712A (zh) * | 2017-12-28 | 2019-07-05 | 上海细胞治疗研究院 | 特异性靶向cd19抗原且高水平稳定表达pd-1抗体的car-t细胞及用途 |
CN111549062A (zh) * | 2020-05-07 | 2020-08-18 | 西南大学 | 家蚕基于CRISPR/Cas9系统的全基因组敲除载体文库及构建方法 |
CN112458116A (zh) * | 2020-10-19 | 2021-03-09 | 广州重磅生物科技有限公司 | 一种pd-1敲除的cd19car-t细胞的构建方法 |
CN114032213A (zh) * | 2021-08-26 | 2022-02-11 | 山东兴瑞生物科技有限公司 | 一种含有人PD1基因sgRNA的T细胞及其应用 |
CN114181967A (zh) * | 2021-11-22 | 2022-03-15 | 东莞市麦亘生物科技有限公司 | 一种能同时表达cd19 car和敲除t细胞表面pd-1表达的质粒结构及构建方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106399375A (zh) * | 2016-08-31 | 2017-02-15 | 南京凯地生物科技有限公司 | 利用CRISPR/Cas9敲除人PD‑1基因构建靶向CD19CAR‑T细胞的方法 |
WO2017030370A1 (ko) * | 2015-08-17 | 2017-02-23 | 서울대학교산학협력단 | 항-코티닌 항체가 연결된 키메라 항체 수용체 및 이의 용도 |
CN106480097A (zh) * | 2016-10-13 | 2017-03-08 | 南京凯地生物科技有限公司 | 利用CRISPR/Cas9技术敲除人PD‑1基因构建可靶向MSLN新型CAR‑T细胞的方法及其应用 |
WO2017061615A1 (ja) * | 2015-10-08 | 2017-04-13 | 国立大学法人名古屋大学 | キメラ抗原受容体を発現する遺伝子改変t細胞の調製方法 |
CN106916789A (zh) * | 2017-04-27 | 2017-07-04 | 尚小云 | 一种制备分泌il‑12cd19car‑t细胞的方法 |
-
2017
- 2017-07-04 CN CN201710539385.2A patent/CN107119021A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017030370A1 (ko) * | 2015-08-17 | 2017-02-23 | 서울대학교산학협력단 | 항-코티닌 항체가 연결된 키메라 항체 수용체 및 이의 용도 |
WO2017061615A1 (ja) * | 2015-10-08 | 2017-04-13 | 国立大学法人名古屋大学 | キメラ抗原受容体を発現する遺伝子改変t細胞の調製方法 |
CN106399375A (zh) * | 2016-08-31 | 2017-02-15 | 南京凯地生物科技有限公司 | 利用CRISPR/Cas9敲除人PD‑1基因构建靶向CD19CAR‑T细胞的方法 |
CN106480097A (zh) * | 2016-10-13 | 2017-03-08 | 南京凯地生物科技有限公司 | 利用CRISPR/Cas9技术敲除人PD‑1基因构建可靶向MSLN新型CAR‑T细胞的方法及其应用 |
CN106916789A (zh) * | 2017-04-27 | 2017-07-04 | 尚小云 | 一种制备分泌il‑12cd19car‑t细胞的方法 |
Non-Patent Citations (2)
Title |
---|
SHOJI SAITO,ET AL: "Anti-leukemic potency of piggyBac-mediated CD19-specific T cells against refractory Philadelphia chromosome positive acute lymphoblastic leukemia", 《CYTOTHERAPY》 * |
TANG X-Y,ET AL: "Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol", 《BMJ OPEN》 * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107699547A (zh) * | 2017-09-05 | 2018-02-16 | 上海科技大学 | Pd‑1基因沉默的靶向cd133的car t细胞及其应用 |
CN109837244A (zh) * | 2017-11-25 | 2019-06-04 | 深圳宾德生物技术有限公司 | 一种敲除pd1的靶向cd19的嵌合抗原受体t细胞及其制备方法和应用 |
CN109971712A (zh) * | 2017-12-28 | 2019-07-05 | 上海细胞治疗研究院 | 特异性靶向cd19抗原且高水平稳定表达pd-1抗体的car-t细胞及用途 |
CN108531457A (zh) * | 2018-04-10 | 2018-09-14 | 杭州荣泽生物科技有限公司 | 一种Cas9/RNP敲除T细胞PD-1和LAG3基因及制备CAR-T细胞的方法 |
CN108440674A (zh) * | 2018-04-28 | 2018-08-24 | 杭州荣泽生物科技有限公司 | 一种Trop-2特异性嵌合抗原受体细胞制备及其用途 |
CN108913718A (zh) * | 2018-07-20 | 2018-11-30 | 苏州茂行生物科技有限公司 | 一种靶向EGFR vⅢ的CAR-T细胞的制备方法及应用 |
CN109652380A (zh) * | 2019-01-25 | 2019-04-19 | 苏州茂行生物科技有限公司 | 基于碱基编辑靶向LewisY的CAR-T细胞及其制备方法和应用 |
CN109652380B (zh) * | 2019-01-25 | 2023-04-28 | 苏州茂行生物科技有限公司 | 基于碱基编辑靶向LewisY的CAR-T细胞及其制备方法和应用 |
CN111549062A (zh) * | 2020-05-07 | 2020-08-18 | 西南大学 | 家蚕基于CRISPR/Cas9系统的全基因组敲除载体文库及构建方法 |
CN112458116A (zh) * | 2020-10-19 | 2021-03-09 | 广州重磅生物科技有限公司 | 一种pd-1敲除的cd19car-t细胞的构建方法 |
CN112458116B (zh) * | 2020-10-19 | 2023-04-14 | 广州重磅生物科技有限公司 | 一种pd-1敲除的cd19car-t细胞的构建方法 |
CN114032213A (zh) * | 2021-08-26 | 2022-02-11 | 山东兴瑞生物科技有限公司 | 一种含有人PD1基因sgRNA的T细胞及其应用 |
CN114181967A (zh) * | 2021-11-22 | 2022-03-15 | 东莞市麦亘生物科技有限公司 | 一种能同时表达cd19 car和敲除t细胞表面pd-1表达的质粒结构及构建方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107119021A (zh) | Pd‑1敲除cd19car‑t细胞的制备 | |
KR20220119176A (ko) | B 세포 악성종양 및 다른 암을 치료하는데 유용한 자가 t 세포 및 그의 조성물의 생산 방법 | |
CN108864310A (zh) | 一种靶向间皮素并携带PD-Ll阻断剂的CAR-T细胞的构建及其应用 | |
CN110023498A (zh) | 用于产生具有非功能性t细胞受体(tcr)的t细胞的试剂、包含其的组合物及其用途 | |
CN112921054B (zh) | 一种用于治疗β-地中海贫血的慢病毒载体及其制备方法和应用 | |
CN106916789A (zh) | 一种制备分泌il‑12cd19car‑t细胞的方法 | |
CN104593413A (zh) | 利用家蚕后部丝腺合成分泌人血清白蛋白的方法 | |
US20030053988A1 (en) | Inducible alphaviral gene expression system | |
CN109694875B (zh) | 抗CII嵌合抗原受体编码基因、慢病毒质粒、Treg免疫细胞及其应用 | |
CN104962576B (zh) | 一种柱状黄杆菌基因定向敲除质粒及应用 | |
CN101838663A (zh) | 一种大肠杆菌-棒状杆菌穿梭组成型表达载体及其构建方法 | |
CN112813038A (zh) | 一株表达asfv结构囊膜蛋白的prrs病毒及其构建方法与应用 | |
CN110452893B (zh) | 一种高保真CRISPR/AsCpf1突变体的构建及其应用 | |
CN113755442B (zh) | 一种用于药物活性测定的细胞株及其制备方法与应用 | |
KR102292657B1 (ko) | 암 상살 능력이 향상된 면역세포 | |
CN111041027B (zh) | 一种Atg12基因敲除细胞系构建方法及其应用 | |
CN108949800B (zh) | 一种高效便利定位基因插入座位的丝状真菌遗传转化系统及其应用 | |
CN107267538A (zh) | 一种植物质体表达载体的构建方法及应用 | |
CN114939109B (zh) | 一种用于体内产生car-m的脂质纳米颗粒及其制备方法和应用 | |
CN110331170A (zh) | 一种双重gRNA的基因表达元件及其构建方法与应用 | |
CN110117622A (zh) | 一种CRISPR/Cas基因编辑系统及其制备方法和应用 | |
CN109777829A (zh) | 一种基因编辑U6启动子驱动的sgRNA表达组件的构建方法 | |
CN106591369A (zh) | 一种应用腺病毒系统靶向编辑水牛18S rDNA基因的方法 | |
KR102587454B1 (ko) | T 세포 수용체, t 세포 수용체를 포함하는 면역 세포 및 이를 이용하는 방법 | |
KR102476901B1 (ko) | 대장암 세포 특이적 감염 뉴캐슬병 바이러스를 이용한 대장암 치료용 암용해성 바이러스 및 이를 이용한 대장암 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Wang Xiaoping Inventor after: Xu Xianjin Inventor after: Liu Huiying Inventor after: Zhang Feng Inventor before: Shang Xiaoyun Inventor before: Zhang Linlin Inventor before: Li Guanglei |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20180129 Address after: Suzhou City, Jiangsu Province, Suzhou Industrial Park 215126 Xinghu Street No. 218 Biomedical Industry Park building 304 unit A4 Applicant after: Suzhou Mao hang Bio Technology Co., Ltd. Address before: 518067 south of Nanshan District Jingyuan mansion, Nanshan District, Shenzhen, Guangdong Province, 20A Applicant before: Wang Xiaoping |
|
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170901 |